A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment can be reversed.
Not only were improvements sustained, but some patients returned to work, regained their ability to speak different languages, and showed an increase in brain matter volume after just a few months.
“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” says one of the team, Dale Bredesen, University of California, Los Angeles. “Follow up testing showed some of the patients going from abnormal to normal.”
The study investigated the effects of a new kind of personalised treatment on the cognitive abilities of 10 patients who were experiencing age-related decline.
The treatment – called metabolic enhancement for neurodegeneration, or MEND – is based on 36 different factors, including changes in diet, exercise, and sleeping habits, plus the integration of certain drugs, vitamins, and brain stimulation therapy to their regular routine.
These lifestyle changes and treatments were sustained for five to 24 months, and the team from UCLA and the Buck Institute for Research on Ageing in California reports that many of the patients showed real, life-altering improvements as a result.
According to the researchers, this is the first study to objectively show that memory loss in patients can be reversed, and improvement sustained.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” says Bredesen.
Publishing their results in the journal Aging, the team hasn’t gone into much detail about how MEND works, probably because each treatment involves a complex combination of factors that has been specifically designed to treat just one individual, as each person’s version of Alzheimer’s appears to be different.
But they do mention something that all but one of the patients have in common – they are all at genetic risk for Alzheimer’s disease, carrying at least one copy of the APOE4 allele. Five of the patients are carrying two copies of APOE4, which gives them a 10- to 12-fold increased risk of developing the disease, the team explains.
This means there could be some benefit in getting tested for this genetic risk, because patients might finally be able to do something to stall the progression of the disease. Around 65 percent of Alzheimer’s cases in the US involve APOE4.
“We’re entering a new era,” says Bredesen. “The old advice was to avoid testing for APOE because there was nothing that could be done about it. Now we’re recommending that people find out their genetic status as early as possible so they can go on prevention.”
The Latest on: APOE4
via Google News
The Latest on: APOE4
- Antioxidant intake may help prevent Alzheimer's disease, suggests studyon October 14, 2021 at 8:30 pm
Oxidative stress is a unifying paradigm of functional and structural brain changes observed in Alzheimer's disease.Researchers team at Mohamed Haddad of the Institut national de la ...
- Studies Suggest Oral Diuretic Pill Could Help Prevent Alzheimer’s Disease in People at Genetic Riskon October 13, 2021 at 5:02 am
Individuals who carry either one or two copies of the APOE4 variant of the APOE gene have a much greater genetic risk for late-onset AD than those who carry the APOE3 variant. It’s also known ...
- Not All Bad? APOE4 Sharpens Memory in Older Peopleon October 9, 2021 at 7:37 am
APOE4, the strongest genetic risk factor for sporadic Alzheimer’s disease, has been tied to slightly better memory in the young. Now, researchers led by Sebastian Crutch and Jonathan Schott, ...
- APOE4 Linked With Better Visual Working Memory in Older Adultson October 8, 2021 at 2:01 am
Joint senior author Professor Jonathan Schott (Dementia Research Centre, UCL Queen Square Institute of Neurology) said: “We have long known that possession of an APOE4 risk gene increases risk for ...
- Alzheimer’s gene may help you think more clearly at firston October 7, 2021 at 4:05 pm
The new research into the gene known as Apoe4 provides clues into how such a common genetic mutation could have persisted, even with such negative effects. About a quarter of the population has at ...
- Dementia: 'Better memory' could be a risk factor for Alzheimer's - surprising findingon October 7, 2021 at 12:58 pm
A team of scientists at UCL have found that having the Alzheimer’s risk gene - APOE4 - is linked with better performance on tests of a cognitive skill known as visual working memory. The UCL ...
- Researchers find potential cognitive benefits of major Alzheimer's risk geneon October 7, 2021 at 12:52 pm
A well-known gene that increases Alzheimer's risk, called APOE4, has now been linked with better visual working memory in older adults, finds a new study led by University College London researchers.
- APOE4: Potential cognitive benefits of the major Alzheimer’s risk geneon October 7, 2021 at 8:00 am
Alzheimer's Research UK funded research has found that having the Alzheimer’s risk gene, APOE4 is linked with better performance on tests of a cognitive skill known as visual working memory.
- In Oldest Old, Rare Longevity Variants Suppress Common Pathogenic Oneson September 18, 2021 at 9:15 am
Centenarians are less likely to develop AD, diabetes, heart disease. APOE4 carriers with variants in Wnt signaling genes live longer. The 2,900 oldest old in this study had only slightly fewer common ...
via Bing News